PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
TI  - Canagliflozin Reduces HbA1C in Patients with Stage 3 CKD, with the Change Greater in Patients with Higher eGFR
DP  - 2013 Sep 01
TA  - MD Conference Express
PG  - 13--14
VI  - 13
IP  - 11
4099  - http://mdc.sagepub.com/content/13/11/13.short
4100  - http://mdc.sagepub.com/content/13/11/13.full
AB  - The sodium glucose cotransporter-2 inhibitor canagliflozin reduces HbA1C level in patients with type 2 diabetes mellitus (T2DM) and stage 3 chronic kidney disease (CKD), an effect that is more pronounced with higher levels of estimated glomerular filtration rate (eGFR), according to the results of a pooled analysis. This article presents the results of this pooled analysis of four randomized, double-blind, placebo-controlled Phase 3 trials that compared canagliflozin with placebo in patients with inadequately controlled T2DM and stage 3 CKD.